rs15869

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The ENST00000614259.2(BRCA2):​n.*2420A>C variant causes a non coding transcript exon change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.199 in 1,401,318 control chromosomes in the GnomAD database, including 29,312 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★★).

Frequency

Genomes: 𝑓 0.16 ( 2346 hom., cov: 33)
Exomes 𝑓: 0.20 ( 26966 hom. )

Consequence

BRCA2
ENST00000614259.2 non_coding_transcript_exon

Scores

2

Clinical Significance

Benign reviewed by expert panel U:1B:10

Conservation

PhyloP100: 0.0360

Publications

46 publications found
Variant links:
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]
BRCA2 Gene-Disease associations (from GenCC):
  • breast-ovarian cancer, familial, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), ClinGen
  • Fanconi anemia complementation group D1
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, ClinGen, G2P
  • pancreatic cancer, susceptibility to, 2
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • sarcoma
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • hereditary breast ovarian cancer syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Fanconi anemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
  • medulloblastoma
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
BP6
Variant 13-32398875-A-C is Benign according to our data. Variant chr13-32398875-A-C is described in ClinVar as Benign. ClinVar VariationId is 125927.Status of the report is reviewed_by_expert_panel, 3 stars.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.219 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
BRCA2NM_000059.4 linkc.*105A>C 3_prime_UTR_variant Exon 27 of 27 ENST00000380152.8 NP_000050.3 P51587

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
BRCA2ENST00000614259.2 linkn.*2420A>C non_coding_transcript_exon_variant Exon 26 of 26 2 ENSP00000506251.1 A0A7P0TAP7
BRCA2ENST00000380152.8 linkc.*105A>C 3_prime_UTR_variant Exon 27 of 27 5 NM_000059.4 ENSP00000369497.3 P51587
BRCA2ENST00000530893.7 linkc.*105A>C 3_prime_UTR_variant Exon 27 of 27 1 ENSP00000499438.2 A0A590UJI7
BRCA2ENST00000614259.2 linkn.*2420A>C 3_prime_UTR_variant Exon 26 of 26 2 ENSP00000506251.1 A0A7P0TAP7

Frequencies

GnomAD3 genomes
AF:
0.157
AC:
23820
AN:
152148
Hom.:
2348
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0434
Gnomad AMI
AF:
0.279
Gnomad AMR
AF:
0.116
Gnomad ASJ
AF:
0.137
Gnomad EAS
AF:
0.223
Gnomad SAS
AF:
0.230
Gnomad FIN
AF:
0.213
Gnomad MID
AF:
0.218
Gnomad NFE
AF:
0.214
Gnomad OTH
AF:
0.166
GnomAD4 exome
AF:
0.204
AC:
255301
AN:
1249052
Hom.:
26966
Cov.:
17
AF XY:
0.204
AC XY:
126307
AN XY:
618432
show subpopulations
African (AFR)
AF:
0.0366
AC:
981
AN:
26782
American (AMR)
AF:
0.103
AC:
2603
AN:
25200
Ashkenazi Jewish (ASJ)
AF:
0.139
AC:
2928
AN:
21094
East Asian (EAS)
AF:
0.191
AC:
6804
AN:
35554
South Asian (SAS)
AF:
0.211
AC:
13960
AN:
66100
European-Finnish (FIN)
AF:
0.213
AC:
7830
AN:
36732
Middle Eastern (MID)
AF:
0.233
AC:
878
AN:
3774
European-Non Finnish (NFE)
AF:
0.213
AC:
209145
AN:
981472
Other (OTH)
AF:
0.194
AC:
10172
AN:
52344
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
9676
19352
29027
38703
48379
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
7112
14224
21336
28448
35560
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.156
AC:
23811
AN:
152266
Hom.:
2346
Cov.:
33
AF XY:
0.156
AC XY:
11629
AN XY:
74432
show subpopulations
African (AFR)
AF:
0.0432
AC:
1798
AN:
41576
American (AMR)
AF:
0.116
AC:
1773
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
0.137
AC:
477
AN:
3470
East Asian (EAS)
AF:
0.224
AC:
1161
AN:
5182
South Asian (SAS)
AF:
0.230
AC:
1112
AN:
4830
European-Finnish (FIN)
AF:
0.213
AC:
2254
AN:
10586
Middle Eastern (MID)
AF:
0.228
AC:
67
AN:
294
European-Non Finnish (NFE)
AF:
0.214
AC:
14568
AN:
68002
Other (OTH)
AF:
0.164
AC:
347
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
1003
2005
3008
4010
5013
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
276
552
828
1104
1380
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.192
Hom.:
5895
Bravo
AF:
0.144

ClinVar

Significance: Benign
Submissions summary: Uncertain:1Benign:10
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:1Benign:3
Dec 17, 2010
Breast Cancer Information Core (BIC) (BRCA2)
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Jan 12, 2015
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)
Significance:Benign
Review Status:reviewed by expert panel
Collection Method:curation

Class 1 not pathogenic based on frequency >1% in an outbred sampleset. Frequency 0.229 (Asian), 0.01626 (African), 0.2124 (European), derived from 1000 genomes (2012-04-30). -

Oct 09, 2014
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:3
-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

#N/A -

-
Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Nov 01, 2017
GeneKor MSA
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
Nov 22, 2023
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Fanconi anemia complementation group D1 Benign:1
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Hereditary cancer-predisposing syndrome Benign:1
Nov 19, 2014
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.86
CADD
Benign
3.2
DANN
Benign
0.43
PhyloP100
0.036
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs15869; hg19: chr13-32973012; COSMIC: COSV100583075; COSMIC: COSV100583075; API